CD95-Mediated Apoptosis in Acute Myeloid Leukemia (AML): Dependence on Maturational Stage and Growth Characteristics in Vitro

[1]  Shigeki Tanaka,et al.  Fas/APO‐1 (CD95)‐mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin‐2‐activated T cells , 1997, British journal of haematology.

[2]  J. D. Young,et al.  Lymphocyte-mediated cytolysis and disease. , 1996, The New England journal of medicine.

[3]  Seok Lee,et al.  Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic response to chemotherapy , 1996, British journal of haematology.

[4]  C. Sebban,et al.  Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia. , 1996, Leukemia.

[5]  S. Farrow,et al.  New members of the Bcl-2 family and their protein partners. , 1996, Current opinion in genetics & development.

[6]  A. N. Veselkov,et al.  Submitogenic concentrations of anti-CD3 monoclonal antibody exert antiapoptotic effects in preactivated CD4+ but not CD8+ human T cells. , 1995, Cytokines and molecular therapy.

[7]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[8]  Y. Komada,et al.  Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. , 1995, Blood.

[9]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.

[10]  D. Bradbury,et al.  Comparative quantitative expression of bcl‐2 by normal and leukaemic myeloid cells , 1995, British journal of haematology.

[11]  K. Takatsuki,et al.  Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. , 1995, Blood.

[12]  K. Takenaka,et al.  Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. , 1995, Blood.

[13]  J. Westendorf,et al.  Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. , 1995, Blood.

[14]  M. Pfreundschuh,et al.  Tumor Therapy by Immune Recruitment with Bispecific Antibodies , 1995, Immunological reviews.

[15]  W. Kast,et al.  T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes , 1995, Immunological reviews.

[16]  N. Young,et al.  Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. , 1995, Blood.

[17]  J. Harbott,et al.  Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. , 1995, Leukemia & lymphoma.

[18]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[19]  Y. Shima,et al.  Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. , 1995, Blood.

[20]  T. Takizawa,et al.  Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. , 1994, Blood.

[21]  P. Krammer,et al.  Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. , 1994, Journal of immunology.

[22]  T. Kotani,et al.  Expression of functional Fas antigen on adult T-cell leukemia. , 1994, Leukemia research.

[23]  S. Nagata,et al.  Purification and characterization of the Fas-ligand that induces apoptosis , 1994, The Journal of experimental medicine.

[24]  John Calvin Reed.  Bcl-2 and the regulation of programmed cell death , 1994, The Journal of cell biology.

[25]  Takashi Suda,et al.  Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family , 1993, Cell.

[26]  L. Owen-Schaub,et al.  Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[27]  S. Nagata,et al.  Effect of bcl-2 on Fas antigen-mediated cell death. , 1993, Journal of immunology.

[28]  J. Lotem,et al.  Control of programmed cell death in normal and leukemic cells: new implications for therapy. , 1993, Blood.

[29]  T. Waldmann,et al.  APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. , 1993, Blood.

[30]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[31]  W. van Putten,et al.  Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. , 1993, The New England journal of medicine.

[32]  B. Dörken,et al.  APO‐1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl‐2 oncogene expression , 1993, European journal of immunology.

[33]  T. Miyawaki,et al.  Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. , 1992, Journal of immunology.

[34]  T. Yoshino,et al.  Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemistry and in situ hybridization. , 1992, Blood.

[35]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[36]  L. Owen-Schaub,et al.  DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. , 1992, Cellular immunology.

[37]  M. Pierotti,et al.  bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. , 1992, Blood.

[38]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[39]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[40]  W. Hiddemann,et al.  Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multiparameter analysis. , 1988, Blood.

[41]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[43]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[44]  P. Krammer,et al.  Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. , 1995, Leukemia.

[45]  C. Thompson,et al.  Bcl-2 and Bcl-2-related proteins in apoptosis regulation. , 1995, Current topics in microbiology and immunology.

[46]  G. Majno,et al.  Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.

[47]  G. Fleuren,et al.  T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? , 1994, Immunology today.

[48]  John Calvin Reed,et al.  Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.